NCT06560762

Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

A Phase 1, Open Label, Multiple Ascending Dose Study to Assess Safety and Tolerability of STM-01 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Secretome Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase 1, Open label, Multiple Ascending Dose Study to Assess Safety and Tolerability of STM-01 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

Conditions

• Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions

Type	Name	Description
DRUG	STM01	Neonatal mesenchymal stem cells (nMSCs),

Timeline

• Start date: 2025-03-03
• Primary completion: 2025-12-15
• Completion: 2025-12-15
• First posted: 2024-08-19
• Last updated: 2025-04-06

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study